Venetoclax [2], the first in-class, in-clinic and FDA-approved pure BCL-2 BH3 mimetic has dramatically improved patient care in chronic lymphocytic leukemia (CLL) [3]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.